Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia

被引:15
|
作者
Gallegos, Patrick J. [1 ,2 ,3 ]
Frazee, Lawrence A. [2 ,3 ]
机构
[1] Northeastern Ohio Univ Coll Med & Pharm, Dept Pharm Practice, Rootstown, OH 44272 USA
[2] Northeastern Ohio Univ Coll Med & Pharm, Dept Internal Med, Rootstown, OH 44272 USA
[3] Akron Gen Med Ctr, Dept Pharm, Akron, OH USA
来源
PHARMACOTHERAPY | 2008年 / 28卷 / 03期
关键词
lower urinary tract symptoms; LUTS; benign prostatic hyperplasia; BPH; bladder outlet obstruction; anticholinergics; tolterodine; drug therapy;
D O I
10.1592/phco.28.3.356
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lower urinary tract symptoms (LUTS) are commonly associated with benign prostatic hyperplasia (BPH). The LUTS-BPH complex consists of both voiding and storage symptoms that may overlap with overactive bladder symptoms. Drug therapy for men with LUTS may include alpha(1)-antagonists, 5-alpha-reductase inhibitors, combination therapy, and over-the-counter phytotherapy. Anticholinergic agents are effective in relieving overactive bladder symptoms in patients without bladder outlet obstruction. However, anticholinergic therapy has historically been contraindicated in patients with LUTS associated with BPH because of concerns for developing acute urinary retention. To assess the safety and efficacy of anticholinergic therapies for LUTS associated with BPH, a MEDLINE search and a bibliographic search of the English-language literature were conducted. Two nonrandomized, open-label studies; two randomized trials that assessed anticholinergic therapy alone; and eight trials that assessed anticholinergic therapy in combination with an alpha(1)-antagonist were identified. Trials were of short duration (6-12 wks) and included only men with low postvoid residual volumes at baseline. Small nonsignificant changes were seen in objective measures of urinary function. Several trials demonstrated an increase in postvoid residual with anticholinergic therapy, which was statistically significant in two trials. Despite the increase in postvoid residual, rates of acute urinary retention were low and the drugs were well tolerated. Of the five trials that used a validated symptom scoring scale, two demonstrated subjective improvement in urinary function. Men with symptomatic overactive bladder and BPH who are not adequately relieved with alpha(1)-antagonists may benefit from the addition of an anticholinergic agent. Before starting therapy, however, a postvoid residual volume should be measured to measure to rule out baseline urinary retention.
引用
收藏
页码:356 / 365
页数:10
相关论文
共 50 条
  • [31] Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
    Cindolo, Luca
    Pirozzi, Luisella
    Sountoulides, Petros
    Fanizza, Caterina
    Romero, Marilena
    Castellan, Pietro
    Antonelli, Alessandro
    Simeone, Claudio
    Tubaro, Andrea
    de Nunzio, Cosimo
    Schips, Luigi
    BMC UROLOGY, 2015, 15
  • [32] New and Emerging Technologies in Treatment of Lower Urinary Tract Symptoms From Benign Prostatic Hyperplasia
    Gupta, Nikhil K.
    Gange, Steven N.
    McVary, Kevin T.
    SEXUAL MEDICINE REVIEWS, 2019, 7 (03) : 491 - 498
  • [33] Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
    Yoshida, Masaki
    Origasa, Hideki
    Seki, Narihito
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2017, 9 (03) : 176 - 186
  • [34] Lower urinary tract - A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same?
    Irani, J
    Brown, CT
    van der Meulen, J
    Emberton, M
    BJU INTERNATIONAL, 2003, 92 (09) : 937 - 942
  • [35] Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors
    Ahra Cho
    Bilal Chughtai
    Alexis E. Te
    Current Bladder Dysfunction Reports, 2020, 15 : 60 - 65
  • [36] Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors
    Cho, Ahra
    Chughtai, Bilal
    Te, Alexis E.
    CURRENT BLADDER DYSFUNCTION REPORTS, 2020, 15 (02) : 60 - 65
  • [37] Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function
    Lowe, FC
    BJU INTERNATIONAL, 2005, 95 : 12 - 18
  • [38] A Review of Naftopidil for Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
    Fukuta F.
    Masumori N.
    Current Bladder Dysfunction Reports, 2015, 10 (2) : 160 - 169
  • [39] Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia Patients: Orchestrated by Chronic Prostatic Inflammation and Prostatic Calculi?
    Kim, Sang Hoon
    Jung, Kyu In
    Koh, Jun Sung
    Min, Ki Ouk
    Cho, Su Yeon
    Kim, Hyun Woo
    UROLOGIA INTERNATIONALIS, 2013, 90 (02) : 144 - 149
  • [40] Experience with Uroflowmetry in Evaluation of Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia
    Singla, Sanjeev
    Garg, Ramneesh
    Singla, Ankit
    Sharma, Sandeep
    Singh, Jasdeep
    Sethi, Pulkit
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2014, 8 (04) : NC1 - NC3